drugset / Trial / NCT01216384

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

NCT01216384

Phase 1 Completed 73 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the current study is to investigate the safety and tolerability of BI 671800 HEA in healthy Chinese male volunteers following single oral administration, and healthy Japanese male volunteers following single oral administration and multiple administrations.

Timeline

Start
2010-10
Primary completion
2010-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 671800 Small molecule 50 mg Oral
Subject BI 671800 Small molecule 200 mg Oral
Subject BI 671800 Small molecule 400 mg Oral